Destruction of a Microtubule-Bound MYC Reservoir during Mitosis Contributes to Vincristine's Anticancer Activity.


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
06 2020
Historique:
received: 14 12 2019
revised: 11 02 2020
accepted: 09 03 2020
pubmed: 13 3 2020
medline: 2 6 2021
entrez: 13 3 2020
Statut: ppublish

Résumé

Tightly regulated activity of the transcription factor MYC is essential for orderly cell proliferation. Upon deregulation, MYC elicits and promotes cancer progression. Proteasomal degradation is an essential element of MYC regulation, initiated by phosphorylation at Serine62 (Ser62) of the MB1 region. Here, we found that Ser62 phosphorylation peaks in mitosis, but that a fraction of nonphosphorylated MYC binds to the microtubules of the mitotic spindle. Consequently, the microtubule-destabilizing drug vincristine decreases wild-type MYC stability, whereas phosphorylation-deficient MYC is more stable, contributing to vincristine resistance and induction of polyploidy. PI3K inhibition attenuates postmitotic MYC formation and augments the cytotoxic effect of vincristine. IMPLICATIONS: The spindle's function as a docking site for MYC during mitosis may constitute a window of specific vulnerability to be exploited for cancer treatment.

Identifiants

pubmed: 32161139
pii: 1541-7786.MCR-19-1203
doi: 10.1158/1541-7786.MCR-19-1203
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
Biomarkers, Tumor 0
MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
Vincristine 5J49Q6B70F

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

859-872

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Sabrina Becker (S)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Christina Kiecke (C)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Eva Schäfer (E)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Ursula Sinzig (U)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Lena Deuper (L)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Pablo Trigo-Mourino (P)

Max-Planck Institute for Biophysical Chemistry, Goettingen, Germany.
Analytical Research and Development, Merck & Co., Inc., Kenilworth, New Jersey.

Christian Griesinger (C)

Max-Planck Institute for Biophysical Chemistry, Goettingen, Germany.

Raphael Koch (R)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Zuzanna Rydzynska (Z)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Bjoern Chapuy (B)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Frederike von Bonin (F)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Dieter Kube (D)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Vivek Venkataramani (V)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Hanibal Bohnenberger (H)

Institute of Pathology, University Medicine Goettingen, Goettingen, Germany.

Andreas Leha (A)

Department of Medical Statistics, University Medicine Goettingen, Goettingen, Germany.

Johanna Flach (J)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Sascha Dierks (S)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Holger Bastians (H)

Department of Experimental Oncology, University Medicine Goettingen, Goettingen, Germany.

Brigitte Maruschak (B)

Institute for Neuropathology, University Medicine Goettingen, Goettingen, Germany.

Kamil Bojarczuk (K)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.
Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Mateus de Oliveira Taveira (MO)

Department of Medicine, BIDMC/Harvard Medical School, Boston, Massachusetts.

Lorenz Trümper (L)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany.

Gerburg M Wulf (GM)

Department of Medicine, BIDMC/Harvard Medical School, Boston, Massachusetts.

Gerald G Wulf (GG)

Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany. gerald.wulf@med.uni-goettingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH